CE12009

Use the URI link below to search the Marine Institute Data Discovery Catalogue for datasets relevant to this report.The northwest and west coast (ICES Divisions VIaS & VIIb, c) herring acoustic survey programme was first established in 1994. The summer 2012 survey represents the fifth in the new time series (est. in 2008). The Irish component was carried out to cover, 1) the regions around western Ireland 2) the regions west of Scotland that are usually covered by Marine Scotland and 3) northern sector of the Irish Sea survey (AFBI). The survey was coordinated through the ICES Working Group of International Pelagic Surveys (WGIPS). Combined survey data on herring distribution, abundance and age are used to provide a measure of the relative abundance of herring within the Malin shelf stock complex. Survey data on stock numbers at age are submitted to the ICES Herring Assessment Working Group (HAWG) and used in the annual stock assessment process. The northwest and west coast (ICES Divisions VIaS & VIIb) herring stock is composed of two spawning components, autumn and winter spawners. Spawning covers a large geographical area and extends over a 4-month period from late September through to late March (Molloy et al, 2000). Traditionally, fishing effort has been concentrated on spawning and pre-spawning aggregations. The autumn spawning component, which mostly occurs within VIIb and VIaS, feeds along the shelf break area to the west of the spawning grounds. The winter spawning component is found further north in VIaS. In VIaS, summer distribution extends from close inshore to the shelf break. Components of the winter spawning fish are known to undertake northward feeding migration into VIaN before returning in the winter to spawn along the Irish coast

CE14010

The northwest and west coast (ICES Divisions VIaS & VIIb, c) herring acoustic survey programme was first established in 1994.The summer 2014 survey represents the seventh in the new time series (est. in 2008). The survey was coordinated through the ICES Working Group of International Pelagic Surveys (WGIPS). The Irish component was carried out to cover the statistical rectangles between 53°30’-58°30' N and 12°-5° W as laid out in the WGIPS report (ICES, 2014). Combined survey data on herring distribution, abundance and age are used to provide a measure of the relative abundance of herring within the Malin shelf stock complex. Survey data on stock numbers at age are submitted to the ICES Herring Assessment Working Group (HAWG) and used in the annual stock assessment process.The northwest and west coast (ICES Divisions VIaS & VIIb) herring stock is composed of two spawning components, autumn and winter spawners. Spawning covers a large geographical area and extends over a 4-month period from late September through to late March (Molloy et al, 2000). Traditionally, fishing effort has been concentrated on spawning and pre-spawning aggregations. The autumn spawning component, which mostly occurs within VIIb and VIaS, feeds along the shelf break area to the west of the spawning grounds. The larger winter spawning component is found further north in VIa. In VIaS, summer distribution extends from close inshore to the shelf break. Components of the winter spawning fish are known to undertake northward feeding migration into VIaN before returning in the winter to spawn along the Irish coast

CE11008

Use the URI link below to search the Marine Institute Data Discovery Catalogue for datasets relevant to this report.The northwest and west coast (ICES Divisions VIaS & VIIb, c) herring acoustic survey programme was first established in 1994. Prior to acoustic estimation, a larval survey programme was conducted from 1981-1986. In the early 1990s, the ICES herring working group (HAWG) identified the need for a dedicated herring acoustic survey in this area (Anon, 1994). From 1994 to 1996 surveys were carried out on this stock during the summer feeding phase. In 1997 a two-survey spawning survey was established covering both autumn and winter components. In 2004, this was modified into single spawning stock survey was carried out early in quarter 1 which continued until 2007. In 2008, it was decided that this survey should be incorporated into the larger coordinated Malin shelf survey on recommendation from SGHERWAY and WGHAWG. The summer 2011 survey represents the forth in the new time series (est. in 2008). The Irish component was carried out to cover, 1) the regions around western Ireland 2) the regions west of Scotland that are usually covered Marine Scotland and 3) northern sector of the Irish Sea survey (AFBI). The survey was coordinated through the ICES Working Group of International Pelagic Surveys (WGIPS). Combined survey data on herring distribution, abundance and age are used to provide a measure of the relative abundance of herring within the Malin shelf stock complex. Survey data on stock numbers at age are submitted to the ICES Herring Assessment Working Group (HAWG) and used in the annual stock assessment process. The northwest and west coast (ICES Divisions VIaS & VIIb) herring stock is composed of 2 of spawning components, autumn and winter spawners. Spawning covers a large geographical area and extends over a 4-month period from late September through to late March (Molloy et al, 2000). Traditionally fishing effort has been concentrated on spawning and pre-spawning aggregations. The autumn spawning component, which mostly occurs within VIIb and VIaS, feeds along the shelf break area to the west of the spawning grounds. The winter spawning component is found further north in VIaS. In VIaS, summer distribution extends from close inshore to the shelf break. Components of the winter spawning fish are known to undertake northward feeding migration into VIaN before returning in the winter to spawn along the Irish coast

The Labadie, Jones and Cockburn Banks Nephrops Grounds (FU2021) 2023 UWTV Survey Report and catch scenarios for 2024

This report provides the main results of the 2023 underwater television survey on the ‘Labadie, Jones and Cockburn Banks’ ICES assessment area; Functional Unit 2021. The 2023 annual survey was multi-disciplinary in nature collecting UWTV and other ecosystem data. A total of 100 UWTV stations were completed at 6 nm intervals over a randomised isometric grid design. The 2023 mean burrow density was 0.104 burrows/m2 compared with 0.101 burrows/m2 in the year 2022. The 2023 geostatistical abundance estimate was 1026 million, a 0.6% decrease on the abundance from 2022, with a CV of 4%, which is well below the upper limit of 20% recommended by SGNEPS 2012. Low to medium densities were observed throughout the ground. Using the 2023 estimate of abundance and updated stock data implies catch in 2024 that correspond to the ICES MSY approach of 1865 tonnes assuming that discard rates and fishery selection patterns do not change from the average of 2020– 2022. Two species of sea-pen (Virgularia mirabilis and Pennatula phosphorea) were recorded as present at the stations surveyed. Trawl marks were observed at 20% of the stations surveyed.Marine Institut

The “Smalls” Nephrops Grounds (FU22) 2023 UWTV Survey Report and catch scenarios for 2024

This report provides the main results and findings of the eighteenth annual underwater television survey on the ‘Smalls grounds’ ICES assessment area; Functional Unit 22. The survey was multi-disciplinary in nature collecting UWTV and other ecosystem data. A total of 41 UWTV stations were surveyed successfully (high quality image data), carried out over an isometric grid at 4.5nmi or 8.3km intervals. The precision, with a CV of < 7%, was well below the upper limit of 20% recommended by SGNEPS (ICES, 2012). The 2023 abundance estimate was 13% lower than in 2022 and at 776 million is below the MSY Btrigger reference point (990 million). Using the 2023 estimate of abundance and updated stock data implies catch in 2024 that correspond to the ICES MSY approach of 1912 tonnes, assuming that discard rates and fishery selection patterns do not change from the average of 2020 - 2022. One species of sea pen was recorded as present at the stations surveyed: Virgularia mirabilis. Trawl marks were observed at 37% of the stations surveyed.Marine Institut

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

FU19 Nephrops Grounds 2023 UWTV Survey Report and catch scenarios for 2024

This report provides the main results of the fourteenth underwater television survey of the various Nephrops patches in Functional Unit 19. The survey was multi disciplinary in nature collecting UWTV and other ecosystem data. In 2023 a total 42 UWTV stations were successfully completed. The mean density estimates varied considerably across the different patches. The 2023 raised abundance estimate showed a 15% decrease from the 2022 estimate and at 220 million burrows is below the MSY Btrigger reference point (430 million). Using the 2023 estimate of abundance and updated stock data implies catch in 2024 that correspond to the F ranges in the EU multi annual plan for Western Waters are between 224 and 248 tonnes (assuming that discard rates and fishery selection patterns do not change from the average of 2020–2022). One species of sea pen was observed; Virgularia mirabilis which has been observed on previous surveys of FU19. Trawl marks were observed at 10% of the stations surveyed.Marine Institut

A meta-analysis of genome-wide association studies of epigenetic age acceleration

Funding: Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). Genotyping and DNA methylation profiling of the GS samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award “STratifying Resilience and Depression Longitudinally” ((STRADL) Reference 104036/Z/14/Z)). Funding details for the cohorts included in the study by Lu et al. (2018) can be found in their publication. HCW is supported by a JMAS SIM fellowship from the Royal College of Physicians of Edinburgh and by an ESAT College Fellowship from the University of Edinburgh. AMM & HCW acknowledge the support of the Dr. Mortimer and Theresa Sackler Foundation. SH acknowledges support from grant 1U01AG060908-01. REM is supported by Alzheimer’s Research UK major project grant ARUK-PG2017B-10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Data Availability: Summary statistics from the research reported in the manuscript will be made available immediately following publication on the Edinburgh Data Share portal with a permanent digital object identifier (DOI). According to the terms of consent for Generation Scotland participants, requests for access to the individual-level data must be reviewed by the GS Access Committee ([email protected]). Individual-level data are not immediately available, due to confidentiality considerations and our legal obligation to protect personal information. These data will, however, be made available upon request and after review by the GS access committee, once ethical and data governance concerns regarding personal data have been addressed by the receiving institution through a Data Transfer Agreement.Peer reviewedPublisher PD

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention